May 12, 2017 6:54pm

 

They’re sued for a death, about to be for a potential patent infringement (Nanofibers); they’re running out of cash, with an on-going concern qualification, a pending NASDAQ de-listing, a reverse split and a shaky warrant exercise and …

 

Still without a peer reviewed manuscript to support “any” scientific advance, an approved IND or clinical trials after blowing through $33 million + and $1 billion in convertible debt that has been issued in the past three years

Any new investors will be paying off the litigant and its lawyers …

Unless there is a “Hail Mary”, the short-term step – a bankruptcy petition in my view !

 

Pre-open indications: 1 hit

 

As the leading voice of cell therapy investors; I am not always a doom and gloom reporter but a man who has been “there” with the gray hair and a readership following with real numbers to prove it!

 

I answer one question, in which company should investors commit and keep their money

 

 

 

RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.

 

 

Henry’omics:

From the pre-open’s investor’s newsletter “shouldn’t material events be timely issued? Biostage (BSTG) got sued for a wrongful death complaint …”

Reiterating, ““A complaint seeks payment for an unspecified amount of damages and alleges that the plaintiff sustained … terminal … injuries allegedly caused by products, including synthetic trachea scaffolds and bioreactors, provided by certain of the named defendants and utilized in connection with surgeries performed by third parties in 2012 and 2013.”

… Timely disclosure?  Yet, “The Company did and has contacted its liability insurance carriers to request defense and indemnification of any losses incurred in connection with this lawsuit.”

… This complaint relates to Biostage’s (BSTG) first generation trachea scaffold technology …

… Past problems/issues continue to come to light as an IND was about to facilitate a small clinical trial!”

​

WHY, hasn't the CEO stepped out in fron of this issue ... and only relied on a 10-Q ...

​Maybe, the CMO and president should comment ... he was on "the case" at the time ...

​

Investors DESERVE better ... disclosure !!

.

 

Daily analytics:

U.S. equities closed DOWN on Friday … with the DOW closing down -0.11% (-22.81) as the NASDAQ also closed up +0.09% (+5.27) …

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded below 10 ….

  • Thursday closed near 10.6 following Wednesday ‘s near 10,Tuesday traded below 10, not seen since December 2006 while Monday traded near 10 after last Friday’s near 10.7;

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated a negative -0.48% at the pre-open was and closed Friday DOWN -0.53% after Thursday’s -0.64%, Wednesday’s+0.62% following Tuesday’s -0.03% versus last Monday’s -0.24%;

… The iShares NASDAQ Biotechnology (IBB) did NOT indicate in the pre-open and closed Friday UP +0.45% after Thursday’s -019% after Wednesday’s -0.34% following Tuesday’s +1.21% versus Monday’s -2.17%

 

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The open was negative  with an A/DL of 17/20 and 6 flats ;

·         The mid-day jumped positive with an A/DL of 30/11 and 2 flats;

·         The close stayed positive with an A/DL of 30/12 and 1 flat;

 

 

The count - decliners versus gainers: look at the differences in the spreads and advance/decline lines:

·         Friday’s decliners ranged from -0.13% <MDXG> to -61.97% <CAPR> in 12 equities;

·         Thursday’s decliners ranged from -0.20% <CLBS> to -5.04% <AGTC> in 21 equities;

·         Wednesday’s decliners ranged from -0.48% <VTGN> to -7.92% <RGNX> in 14 equities;

·         Tuesday’s decliners ranged from -0.07% <MDXG> to -27.70% <CUR> in 22 equities;

·         Monday’s decliners ranged from -0.65% <CAPR> to -13.56% <CUR> in 28 equities;

Versus

·         Friday’s gainers ranged from +0.40% <BLUE> to +17.14% <SGMO> in 30 equities;

·         Thursday’s gainers ranged from +0.09% <KITE> to +60.92% <SGMO> in 19 equities;

·         Wednesday’s gainers ranged from +0.03% <OPXA> to +36.18% <CUR> in 27 equities;

·         Tuesday’s gainers ranged from +0.04% <CLLS> to +6.41% <JUNO> in 18 equities;

·         Monday’s gainers ranged from +0.37% <ONVO> to +11.84% <OSIR> in 12 equities;

 

 

Pre-open indications: 1 hit and 0 miss

  • Biostage (BSTG) closed down -$0.00 or -0.47% to $0.32

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.